Nafithromycin is under clinical development by Wockhardt and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Nafithromycin’s likelihood of approval (LoA) and phase transition for Respiratory Tract Infections took place on 31 Aug 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nafithromycin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Nafithromycin overview

Nafithromycin (WCK-4873) is under development for the treatment of community-acquired bacterial pneumonia and respiratory tract infections. The drug candidate is administered orally and intravenously. It is a ketolide. The drug candidate targets 23s ribosomal subunit. It was also under development for the treatment of multi-drug resistant Streptococcus pneumoniae (pneumococcus) infections and Haemophilus influenza infections.

Wockhardt overview

Wockhardt is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, formulations and biosimilars. The company’s product portfolio caters to various therapeutic areas including orthopedics, dental care, dermatology, rheumatology, gynecology, pediatrics, cardiology, pain management, nephrology, neurology, and diabetes. It also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, novel drug delivery systems (NDDS). The company operates in India, the US, the UK, Ireland, Dubai, U.A.E. and has market presence in Brazil, France, Russia, Vietnam, Mexico, Philippines, Kenya, Nigeria, Ghana and others. Wockhardt is headquartered in Mumbai, Maharashtra, India.

Quick View Nafithromycin LOA Data

Report Segments
  • Innovator
Drug Name
  • Nafithromycin
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Infectious Disease
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.